Adaptimmune Therapeutics Plc (ADAP)

Currency in USD
0.078
-0.006(-7.23%)
Closed·
After Hours
0.080+0.003(+3.23%)
·
ADAP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ADAP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0750.083
52 wk Range
0.0711.330
Key Statistics
Prev. Close
0.083
Open
0.083
Day's Range
0.075-0.083
52 wk Range
0.071-1.33
Volume
26.81M
Average Volume (3m)
16.59M
1-Year Change
-92.1%
Book Value / Share
-0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADAP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.714
Upside
+815.38%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Adaptimmune Therapeutics Plc Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Employees
506

Adaptimmune Therapeutics Plc SWOT Analysis


TCR-T Breakthrough
Adaptimmune's early FDA approval of Tecelra for synovial sarcoma marks a significant milestone in T-cell receptor engineered therapies
Financial Crossroads
Despite impressive revenue growth, Adaptimmune faces challenges with negative EPS forecasts and a revised cash runway extending into late 2025
Market Dynamics
Explore Adaptimmune's pioneering position in the TCR-T market, balanced against the $727,000 list price for Tecelra and potential adoption hurdles
Future Prospects
Analyst price targets hover around $1.00, reflecting cautious optimism as Adaptimmune navigates commercialization challenges and pipeline development
Read full SWOT analysis

Adaptimmune Therapeutics Plc Earnings Call Summary for Q4/2024

  • Q4 2024 product revenue at $1.2M; targeting $25M sales in 2025 with 3-4x revenue increase expected in Q1 2025
  • Stock fell 4.01% premarket despite 146% revenue growth in last 12 months; market cap at $115M suggests potential undervaluation
  • Strategic cost reductions aim to save $75-100M over 4 years; company targets profitability by 2027
  • TCELLRA launch successful with 20 treatment centers; plans to expand to 30 by end of 2025
  • CEO optimistic about sales acceleration; exploring partnerships and monetization opportunities for future growth
Last Updated: 20/03/2025, 14:12
Read Full Transcript

Compare ADAP to Peers and Sector

Metrics to compare
ADAP
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.8x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
−0.6x0.7x2.6x
Price / LTM Sales
0.1x4.5x3.3x
Upside (Analyst Target)
-329.2%43.5%
Fair Value Upside
Unlock34.8%6.8%Unlock

Analyst Ratings

0 Buy
6 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.714
(+815.38% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.03 / -0.12
Revenue / Forecast
7.29M / 7.55M
EPS Revisions
Last 90 days

ADAP Income Statement

People Also Watch

0.04
GIBO
0.00%
0.032
NCNA
-3.05%
0.0695
RAYA
+14.49%
5.670
GVH
+9.88%

FAQ

What Stock Exchange Does Adaptimmune Therapeutics Trade On?

Adaptimmune Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Adaptimmune Therapeutics?

The stock symbol for Adaptimmune Therapeutics is "ADAP."

What Is the Adaptimmune Therapeutics Market Cap?

As of today, Adaptimmune Therapeutics market cap is 20.54M.

What Is Adaptimmune Therapeutics's Earnings Per Share (TTM)?

The Adaptimmune Therapeutics EPS (TTM) is -0.27.

When Is the Next Adaptimmune Therapeutics Earnings Date?

Adaptimmune Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is ADAP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Adaptimmune Therapeutics Stock Split?

Adaptimmune Therapeutics has split 0 times.

How Many Employees Does Adaptimmune Therapeutics Have?

Adaptimmune Therapeutics has 506 employees.

What is the current trading status of Adaptimmune Therapeutics (ADAP)?

As of 09 Aug 2025, Adaptimmune Therapeutics (ADAP) is trading at a price of 0.08, with a previous close of 0.08. The stock has fluctuated within a day range of 0.08 to 0.08, while its 52-week range spans from 0.07 to 1.33.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.